First Trust Exchange-Traded Fund IV FT Energy Income Partners Strategy ETF (ARCA: EIPX)

Últimas noticias sobre First Trust Exchange-Traded Fund IV FT Energy Income Partners Strategy ETF (ARCA:EIPX)

First Trust Exchange-Traded Fund IV FT Energy Income Partners Strategy ETF

Energy

Utilities

Industrials

Other

Technology

Under normal market conditions, the Fund will seek to achieve its investment objective by investing at least 80 percent of its net assets (plus any borrowing for investment purposes) in a portfolio of equity securities in the broader energy market (Energy Companies). Energy Companies include companies in the Global Industry Classification Standard (GICS) energy sector, companies in the GICs utility sector (excluding water utilities), or companies in any other GICS sectors that derive at least 50 percent of their revenues or profits from exploration, development, production, gathering, transportation, processing, storing, refining, distribution, mining or marketing, of natural gas, natural gas liquids (including propane), crude oil, refined petroleum products, petrochemicals, electricity, coal, uranium, hydrogen or other energy sources, renewable energy production, renewable energy equipment, energy storage, carbon, carbon dioxide, carbon dioxide and fugitive methane mitigation and management, as well as electric transmission, distribution, storage and system reliability support. Energy Companies also include companies providing engineering, consulting and construction services that derive at least 50 percent of their revenues or profits from the above, all of which are selected by Energy Income Partners, LLC, the Funds investment sub-advisor (Energy Income Partners or the Sub-Advisor). These companies may include publicly traded master limited partnerships or limited liability companies taxed as partnerships (MLPs) and MLP affiliates.

Enterprise Products Partners Lp

Total Sa Sponsored Adr

Energy Transfer Lp

Shell Plc

Imperial Oil Ltd

Exxon Mobil Corp.

Andeavor Logistics L.p.

Bp Plc ADR

Kinder Morgan Holding

Plains Gp Holdings Lp

Oneok Inc.

FT Energy Income Partners Strategy ETF

Equities

Large Cap

News

Contracts

Media

EIPX

HJEN

SHEL

BP no cree que Venture Global LNG necesite más tiempo para iniciar la producción comercial en su planta Calcasieu Pass.

¿Qué está pasando con las acciones de BP en el premercado del jueves?

Asset Sales

Movers

EIPI

TotalEnergies (TTE) vende TPPL. Este movimiento se alinea con su estrategia de centrarse en mercados de crecimiento y transición.

¿Por qué las acciones de TotalEnergies (TTE) están cayendo el martes?

DA Davidson analyst Gil Luria downgrades CoreWeave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) from Neutral to Underperform and announces $36 price target.

Downgrades

Price Target

Analyst Ratings

CRWV

DA Davidson Downgrades CoreWeave to Underperform, Announces $36 Price Target

Longevity Health Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>), a company focused on extending human longevity and healthy aging through technologically innovative and clinically proven products in regenerative bio-aesthetics, diagnostics, and nutrition ("XAGE", the "Company", "we", "our", or "us"), today announced the following business updates:
1.&nbsp;&nbsp;&nbsp;Merger Agreement entered with 20/20 BioLabs ("20/20")
<ul>
<li>Merger Agreement executed on April 11, 2025, pursuant to which 20/20 is expected to continue as a wholly owned subsidiary of XAGE following merger closing subject to the satisfaction of the conditions set forth in the Merger Agreement.</li>
<li>S-4 prospectus filed with the Securities and Exchange Commission (SEC) on May 8, 2025. &nbsp;</li>
</ul>
2.&nbsp;&nbsp;&nbsp;Unaudited Q1 sales &nbsp;
<ul>
<li>XAGE: approximately $663,000 on a full quarter pro forma basis, an increase of 8% over the same period last year.</li>
<li>20/20: approximately $562,000, an increase of 15% over the same period last year. &nbsp;</li>
</ul>
3.&nbsp;&nbsp;&nbsp;Reverse Stock Split &nbsp;
<ul>
<li>Completed a 1 for 30 reverse stock split of XAGE's common stock on May 12, 2025.</li>
<li>Stock began trading at split adjusted price on May 14, 2025. &nbsp;</li>
</ul>
4.&nbsp;&nbsp;&nbsp;Expected Q2 New Product Launches &nbsp;
<ul>
<li>XAGE: expects to launch a medicated cleanser for use in Physicians' offices and MedSpas. This cleanser will also be marketed to 20/20's customer base which consists predominantly of firefighters.</li>
<li>20/20: expects to launch a new lab test that measures inflammatory biomarkers in the blood, a key contributor to premature aging and precursor to various skin and health disorders. This test will also be marketed to XAGE's customer base of physicians and MedSpas.</li>
<li>20/20: announced an initiative with Giant Food at 9 stores in Maryland and Virginia to offer OneTestTM, their multi-cancer test using capillary blood. Giant is also considering expanding the pilot to include a test that spots biomarkers linked to pro-inflammatory foods.</li>
</ul>
5.&nbsp;&nbsp;&nbsp;Additional Financing
<ul>
<li>XAGE is evaluating options and anticipates announcing a primary investment in Q2 2025.</li>
</ul>

Longevity Health Holdings, Inc. - Common Stock

XAGE

Longevity Health Holdings Unaudited Q1 Sales: XAGE ~$663,000 On A Full Quarter Pro Forma Basis, Up 8% YoY; 20/20 Sales ~$562,000, Up 15% YoY

Pulmatrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PULM#NASDAQ">PULM</a>) reported quarterly losses of $(0.50) per share. This is a 317.39 percent decrease over earnings of $0.23 per share from the same period last year.

Earnings

PULM

Pulmatrix Q1 EPS $(0.50) Down From $0.23 YoY

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies analyst Alejandro Demichelis upgraded Petróleo Brasileiro S.A. &#8211; Petrobras (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>) from Hold to Buy and announced a $15.3 price target. Petrobras Brasileiro shares closed at $12.15 on Wednesday. <a href="https://www.benzinga.com/quote/pbr/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Mitchell Kapoor upgraded the rating for CytomX Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) from Neutral to Buy and maintained the price target of $5. CytomX Therapeutics shares closed at $2.38 on Wednesday. <a href="https://www.benzinga.com/quote/ctmx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank analyst Konark Gupta upgraded the rating for CAE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CAE#TSX">CAE</a>) from Sector Perform to Sector Outperform and announced a C$42 price target. <a href="https://www.benzinga.com/quote/cae/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Aaron Rakers upgraded Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) from Equal-Weight to Overweight and raises the price target from $72 to $75. Cisco shares closed at $61.29 on Wednesday. <a href="https://www.benzinga.com/quote/csco/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying CTMX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="599" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15081526/image-180-1024x599.png" alt="" class="wp-image-916400" style="width:650px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15081526/image-180-1024x599.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15081526/image-180-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15081526/image-180-768x449.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15081526/image-180.png 1133w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45405004/jim-cramer-sofi-goes-to-new-highs-recommends-not-buying-this-health-care-stock">Jim Cramer: SoFi Goes To &#8216;New Highs,&#8217; Recommends Not Buying This Health Care Stock</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

Markets

Trading Ideas

CSCO

CTMX

TSX:CAE

This CytomX Therapeutics Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday

Opus Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRD#NASDAQ">IRD</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.25) by 4 percent. This is a 17.24 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $4.37 million which beat the analyst consensus estimate of $3.10 million by 41.03 percent. This is a 155.41 percent increase over sales of $1.71 million the same period last year.

Earnings Beats

Opus Genetics Q1 EPS $(0.24) Beats $(0.25) Estimate, Sales $4.37M Beat $3.10M Estimate

Cocrystal Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.51) by 54.9 percent. This is a 41.03 percent increase over losses of $(0.39) per share from the same period last year.

COCP

Cocrystal Pharma Q1 EPS $(0.23) Beats $(0.51) Estimate

Canaccord Genuity analyst Susan Anderson maintains Waldencast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) with a Buy and lowers the price target from $6 to $5.

WALD

Canaccord Genuity Maintains Buy on Waldencast, Lowers Price Target to $5

Biotech

General

IMMP

Immutep Announces Announces That A 60.8% Response Rate And 90.2% Disease Control Rate, According To RECIST, Has Been Achieved In The Investigator-Initiated INSIGHT-003 Trial As Of The Data-Cut Off Date Of  May 6

~ Horizon Aircraft's unique Cavorite X7 eVTOL becomes the first aircraft in the world to achieve&nbsp;a stable transition using a novel fan-in-wing design ~
TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- New Horizon Aircraft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>), doing business as Horizon Aircraft, an advanced aerospace engineering company and developer of one of the world's first hybrid eVTOL aircraft, announces that it has <a href="https://www.globenewswire.com/Tracker?data=N4q3nLPFvxBw4qGBp0sa9ocHYr-K2qBIhweFaIgKrMR-iz9Y9wpiMSp4lPYTgT0dwIhtZlbhcq-3HGEA-MZG3Ft_nA-w4BM7m2xwTuCP9vhixL5m0KUVQ52jB9UC0uLm">achieved full wing transition</a> of its large-scale prototype aircraft.

HOVR

Horizon Aircraft's Cavorite X7 Becomes World's First eVTOL To Achieve Stable Transition With Innovative Fan-In-Wing Design

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) with a Buy and maintains $10 price target.

Reiteration

AQST

HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target

On Wednesday, President Donald J. Trump inked a deal with the Qatar government, aiming to create an economic exchange valued at least $1.2 trillion, the White House said in a press release.
Apart from this, President Trump disclosed economic agreements between the United States <a target="_blank" href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-secures-historic-1-2-trillion-economic-commitment-in-qatar/" rel="noreferrer noopener">and</a> Qatar totaling over $243.5 billion, which included a significant sale of Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) aircraft and GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) engines to Qatar Airways for $96 billion.&nbsp;&nbsp;
In particular, Qatar Airways and Boeing disclosed an agreement for the airline to purchase <a href="https://www.benzinga.com/pressreleases/25/05/n45418445/boeing-and-qatar-airways-announce-historic-order-for-up-to-210-widebody-airplanes" target="_blank" rel="noreferrer noopener">up to 210 widebody aircraft</a>.
This deal sets new records as Boeing&#8217;s largest-ever widebody order and includes the most significant order for 787 Dreamliners and Qatar Airways&#8217; single largest aircraft order to date.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/contracts/25/05/45384460/boeing-welcomes-new-saudi-arabian-partner-avilease-orders-20-fuel-efficient-jets" rel="noreferrer noopener">Boeing Welcomes New Saudi Arabian Partner: AviLease Orders 20 Fuel-Efficient Jets</a>
Additionally, GE Aerospace and Qatar Airways announced a substantial expansion <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45422353/ge-aerospace-and-qatar-airways-strengthen-partnership-with-agreement-for-400-ge9x-and-genx-engines" rel="noreferrer noopener">of their long-term collaboration</a>.
Qatar Airways has committed to over 400 engines, including 60 GE9X and 260 GEnx engines, along with additional options and spare units.
This represents the largest widebody engine purchase in GE Aerospace&#8217;s history, intended to power Qatar Airways&#8217; next-generation Boeing 777-9 and Boeing 787 aircraft.
These new agreements reinforce GE Aerospace&#8217;s dedication to Qatar&#8217;s growing aviation sector and build upon a prior order for 188 GE9X engines, bringing the total commitment to 248 of these engines.
Moreover, Parsons Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) won 30 significant projects with a total potential value of up to $97 billion.
Major Defense Deals: RTX Corporation&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) Raytheon secured a $1 billion U.S.-Qatar deal for counter-drone capabilities, making Qatar the first international buyer of Raytheon&#8217;s FS-LIDS.
Also, General Atomics penned an agreement of around $2 billion for Qatar&#8217;s acquisition of the MQ-9B remotely piloted aircraft system.
Apart from this, the U.S. and Qatar inked a statement of intent to further enhance their security partnership, with potential investments exceeding $38 billion, including support for shared responsibilities at Al Udeid Air Base and future defense capabilities.
All the abovementioned deals are expected to generate billions in investments to bolster American manufacturing, fulfilling the commitment to revitalize domestic production and foster economic growth, the White House said in the press release.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45390422/trump-unveils-historic-and-transformative-600-billion-saudi-deal-predicts-markets-will-go-a-lot-higher" target="_blank" rel="noreferrer noopener">Trump Unveils&#8217; Historic And Transformative&#8217; $600 Billion Saudi Deal, Predicts Markets Will &#8216;Go A Lot Higher&#8217;</a></li>
</ul>
Image by Evan El-Amin via Shutterstock

Trump's $1.2 Trillion 'Made in America' Win: Boeing, GE, And Others Secure Qatar Mega-Deal

Vaxart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) today announced that it has received approval from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), to initiate dosing in the 10,000-participant portion of its ongoing Phase 2b clinical trial evaluating its oral pill COVID-19 vaccine candidate.
The Phase 2b trial is a double-blind, multi-center, randomized, comparator-controlled study. It is designed to evaluate the relative efficacy, safety, and immunogenicity of Vaxart's oral COVID-19 vaccine candidate compared to an approved mRNA COVID-19 vaccine in adults who have previously been vaccinated against COVID-19.
Funding for this award was received under Project NextGen, a $5 billion initiative led by BARDA and the National Institute of Allergy and Infectious Diseases (NIAID) to accelerate and streamline the development of the next generation of innovative COVID-19 vaccines, therapeutics, and enablers. Vaxart's project award through the Rapid Response Partnership Vehicle (RRPV) Consortium is valued at up to $460.7 million. This project has been funded with federal funds from HHS; ASPR; and BARDA, under Other Transaction (OT) number 75A50123D00005.
 &nbsp;

VXRT

Vaxart Receives BARDA Approval To Initiate Dosing In 10,000-participant Portion Of Ongoing Phase 2B Clinical Trial Evaluating Oral Pill COVID-19 Vaccine Candidate

Greenland Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTEC#NASDAQ">GTEC</a>) reported quarterly earnings of $0.29 per share. This is a 61.11 percent increase over earnings of $0.18 per share from the same period last year. The company reported $21.68 million in sales this quarter. This is a 4.60 percent decrease over sales of $22.72 million the same period last year.

GTEC

Greenland Technologies Q1 EPS $0.29 Up From $0.18 YoY, Sales $21.68M Down From $22.72M YoY

Adcore (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ADCO#TSX">ADCO</a>) reported quarterly losses of $(0.00) per share. This is a 40 percent increase over losses of $(0.01) per share from the same period last year. The company reported $7.01 million in sales this quarter. This is a 2.11 percent increase over sales of $6.87 million the same period last year.

TSX:ADCO

Adcore Q1 EPS $(0.00) Up From $(0.01) YoY, Sales $7.01M Up From $6.87M YoY

Canaccord Genuity analyst Richard Close maintains HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) with a Hold and lowers the price target from $30 to $29.

HSTM

Canaccord Genuity Maintains Hold on HealthStream, Lowers Price Target to $29

AmpliTech Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>) FY2025 Revenue expected to be more than $21.00M vs $17.00M Est

Guidance

AMPG

AmpliTech Group Sees FY2025  Revenue expected to be more than $21.00M vs $17.00M Est

Despite growing recognition of long COVID as a serious condition, diagnosed patients have no approved treatment options, with many suffering from debilitating fatigue and brain fog
Evidence suggests sustained inflammation plays a central role in the pathogenesis of long COVID, particularly in the associated cognitive dysfunction and other neurological symptoms1
Bezisterim targets key underlying mechanisms of neuroinflammation, and has demonstrated the potential to reduce chronic symptoms in Alzheimer's disease and Parkinson's disease trials thought to be driven by neuroinflammation
CARSON CITY, Nev., May 15, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced first patient enrollment in the Phase 2 ADDRESS-LC clinical trial (<a href="https://www.globenewswire.com/Tracker?data=R-IqdpCs3gs_rEeE54sUQ09HGlhHVrLDi_eNdk6Sd6Cui8hLTSSErT2USBTISodOAsPR_KhmIBGrgFNjSy8T-PlwGG8YccvhcL8Olet5314_yhHDBSm2hwvhJ08MvnKq-QhoF18jy49Fpyfy7_3-iQ==">NCT06847191</a>) evaluating bezisterim (NE3107) for the treatment of neurological symptoms associated with long COVID. The Company anticipates topline data to be available in the first half of 2026.
Long COVID affects approximately 20 million adults in the US, and millions more worldwide.2,3 Studies estimate that approximately 10-30% of individuals who contract COVID-19 experience lingering symptoms for months or even years, with fatigue, brain fog, and cognitive impairment significantly impacting daily functioning and quality of life.4,5 Despite the growing recognition of long COVID as a serious condition, treatment options remain limited, and many patients struggle to find effective relief for their symptoms.

BIVI

BioVie Enrolls First Patient In Phase 2 ADDRESS-LC Clinical Trial Evaluating Bezisterim For Treatment Of Neurological Symptoms Associated With Long COVID; Expects Topline Data To Be Available In H1 2026

Canaccord Genuity analyst Sumant Kulkarni maintains Annovis Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) with a Buy and lowers the price target from $26 to $17.

ANVS

Canaccord Genuity Maintains Buy on Annovis Bio, Lowers Price Target to $17

AmpliTech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 81.25 percent increase over losses of $(0.48) per share from the same period last year. The company reported quarterly sales of $3.60 million which beat the analyst consensus estimate of $3.00 million by 19.97 percent. This is a 56.96 percent increase over sales of $2.29 million the same period last year.

Earnings Misses

AmpliTech Gr Q1 EPS $(0.09) Misses $(0.08) Estimate, Sales $3.60M Beat $3.00M Estimate

Needham analyst Laura Martin reiterates DoubleVerify Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) with a Buy and maintains $18 price target.

Comments

First Trust Exchange-Traded Fund IV FT Energy Income Partners Strategy ETF

Noticias

Últimas noticias sobre First Trust Exchange-Traded Fund IV FT Energy Income Partners Strategy ETF (ARCA:EIPX)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL